ERBB2 and breast cancer: In a case-control study, Souza et al [67] identified a panel of 42 significant differentially expressed miRNAs in 54 (Luminal A, Luminal B, Luminal B HER2+, HER2-, TN) early stage BC patients—among them, 19, 8, 10, 4 of were significantly differentially expressed in Luminal A, Luminal B, Luminal B-HER2+, HER2 enriched types, respectively.